BioNexus Gene Lab Corp (BGLC)
NASDAQ:BGLC
Want to see BGLC full AI Analyst Report?
Total Valuation
BioNexus Gene Lab Corp has a market cap or net worth of $4.93M. The enterprise value is $1.58M.
Market Cap$4.93M
Enterprise Value$1.58M
Share Statistics
BioNexus Gene Lab Corp has 2,417,314 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,417,314
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioNexus Gene Lab Corp’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -35.93%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-35.93%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee247.50K
Profits Per Employee-99.49K
Employee Count30
Asset Turnover0.80
Inventory Turnover9.37
Valuation Ratios
The current PE Ratio of BioNexus Gene Lab Corp is ―. BioNexus Gene Lab Corp’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.99
PB Ratio0.85
Price to Fair Value0.85
Price to FCF-3.91
Price to Operating Cash Flow-2.07
PEG Ratio-0.03
Income Statement
In the last 12 months, BioNexus Gene Lab Corp had revenue of 7.42M and earned -2.98M in profits. Earnings per share was -1.61.
Revenue7.42M
Gross Profit1.09M
Operating Income-3.16M
Pretax Income-2.98M
Net Income-2.98M
EBITDA-2.80M
Earnings Per Share (EPS)-1.61
Cash Flow
In the last 12 months, operating cash flow was -1.83M and capital expenditures -66.51K, giving a free cash flow of -1.90M billion.
Operating Cash Flow-1.83M
Free Cash Flow-1.90M
Free Cash Flow per Share-0.79
Dividends & Yields
BioNexus Gene Lab Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-23.60%
50-Day Moving Average2.32
200-Day Moving Average4.21
Relative Strength Index (RSI)43.18
Average Volume (3m)128.33K
Important Dates
BioNexus Gene Lab Corp upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
BioNexus Gene Lab Corp as a current ratio of 10.46, with Debt / Equity ratio of 2.04%
Current Ratio10.46
Quick Ratio9.16
Debt to Market Cap0.00
Net Debt to EBITDA0.79
Interest Coverage Ratio-161.62
Taxes
In the past 12 months, BioNexus Gene Lab Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioNexus Gene Lab Corp EV to EBITDA ratio is -1.83, with an EV/FCF ratio of -2.73.
EV to Sales0.69
EV to EBITDA-1.83
EV to Free Cash Flow-2.73
EV to Operating Cash Flow-2.79
Balance Sheet
BioNexus Gene Lab Corp has $2.38M in cash and marketable securities with $176.05K in debt, giving a net cash position of $2.21M billion.
Cash & Marketable Securities$2.38M
Total Debt$176.05K
Net Cash$2.21M
Net Cash Per Share$0.91
Tangible Book Value Per Share$4.64
Margins
Gross margin is 14.62%, with operating margin of -42.54%, and net profit margin of -40.20%.
Gross Margin14.62%
Operating Margin-42.54%
Pretax Margin-40.20%
Net Profit Margin-40.20%
EBITDA Margin-37.67%
EBIT Margin-39.93%
Analyst Forecast
The average price target for BioNexus Gene Lab Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-21.93%
EPS Growth Forecast-80.87%